News
-
-
-
-
-
-
-
PRESS RELEASE
THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8 million
THX Pharma launches a €8 million capital increase to fund rare neurological drug development, with 75.5% commitments secured. Batten-1 and TX01 to lead clinical and commercial endeavors with strategic shift to international markets. Investment opportunities for various tax schemes -
-
PRESS RELEASE
Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Heidelberg Pharma's lead ADC candidate HDP-101 granted Fast Track Designation by US FDA for the treatment of multiple myeloma. Accelerated review for innovative cancer therapy -